COMPANY
Kumquat Biosciences
We apply our KRAS pathway expertise to develop single and combination therapies that specifically address undruggable targets, while energizing the immune system to bring about synergistic and lasting therapeutic potential. From company website Source · Oct 13, 2026
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Patent Agent | Kumquat Biosciences | Sep 14, 2026 | Oct 16, 2026 |
Raises and deals from press releases
- Deal Bayer deal · amount not disclosed · announced Aug 12, 2025 Company release ↗
Source quote
- Aug 12, 2025 · Company release ↗
“Berlin, Germany and San Diego, USA – Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclusive global license and collaboration to develop and commercialize Kumquat’s KRAS G12D inhibitor”
- Aug 12, 2025 · Company release ↗
- Deal Takeda deal · up to $130M total · announced Apr 16, 2024 Company release ↗
Source quote
- Apr 16, 2024 · Company release ↗
“Kumquat will receive up to $130 million in near-term payments and potentially more than $1.2 billion if all future clinical, regulatory, and commercial milestones are achieved during the term of the agreement”
- Apr 16, 2024 · Company release ↗
Timeline
- Trial start Phase 2: KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) source ↗
- Trial start Phase 1: A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies source ↗
- Partnership Partnership / licensing announced Aug 12, 2025. Source: company's own press page. source ↗
- Trial start Phase 1: A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies source ↗
- Trial start Phase 1: A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies source ↗
- Trial start Phase 1: A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies source ↗
- Trial start Phase 1: A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies source ↗
- Trial start Phase 1: A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies source ↗
Upcoming milestones
- Dec 31, 2026 (ESTIMATED) · Phase 1 · A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies · NCT06507306
- 2027-03 (ESTIMATED) · Phase 1 · A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies · NCT06645886
- 2027-10 (ESTIMATED) · Phase 2 · KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) · NCT07406633
- Nov 30, 2027 (ESTIMATED) · Phase 1 · A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies · NCT06994806
- Jun 30, 2029 (ESTIMATED) · Phase 1 · A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies · NCT06720987
- 2029-12 (ESTIMATED) · Phase 1 · A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies · NCT07542704
Funding
- Partnership / licensing announced Aug 12, 2025. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 7
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06507306 | A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Active, not recruiting | Jun 3, 2024 | Dec 31, 2026 (estimated) |
| NCT07406633 | KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) | Phase 2 | Recruiting | Jun 23, 2026 | 2027-10 (estimated) |
| NCT07207707 | A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies | Phase 1 | Recruiting | Sep 16, 2025 | 2026-09 (estimated) |
| NCT06720987 | A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Recruiting | Feb 4, 2025 | Jun 30, 2029 (estimated) |
| NCT07542704 | A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies | Phase 1 | Not yet recruiting | 2026-05 | 2029-12 (estimated) |
| NCT06645886 | A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | Phase 1 | Active, not recruiting | Dec 9, 2024 | 2027-03 (estimated) |
| NCT06994806 | A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Recruiting | Jun 24, 2025 | Nov 30, 2027 (estimated) |
Raises and investors new
- InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗
Open jobs 1
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Patent Agent | Kumquat Biosciences | Sep 14, 2026 | Oct 16, 2026 | Entry |
Connect
See your connections at Kumquat Biosciences on LinkedIn (search by name, results not checked)